Phase Forward (ticker: PFWD, exchange: NASDAQ Global Market (.O))
News Release -
Phase Forward to Host Eighth Annual European Users ConferenceEvent to Spotlight Customer Successes and Provide Forum for Sharing
Best Practices and Industry Networking
WALTHAM, Mass., Apr 14, 2010 (BUSINESS WIRE) --Phase Forward (NASDAQ: PFWD), a leading provider of data management
solutions for clinical trials and drug safety, will host its eighth
Users Conference (EUC) April 21 - 22 at the Corinthia Hotel in
Budapest, Hungary. The conference will offer a full day of industry,
product and customer-led sessions.
Company Chairman and CEO, Bob Weiler will commence the plenary session
with a welcome keynote address. Lord Robert Winston, Professor of
Science and Society and Emeritus Professor of Fertility Studies at
Imperial College, will deliver the industry keynote. During his
presentation, Lord Winston will discuss the industry's many recent
innovations and advancements and review what might lie ahead thanks to
the continued adoption of technology.
More than 15 customer-driven sessions will cover a variety of topics and
include presentations by Cancer Research UK, Dana-Farber Cancer
Institute, ICON Clinical Research, INC Research, Novartis Pharma AG,
Quintiles, Servier Pharmaceutical Group, Theravance, UCB and the U.K.
Medicines and Healthcare Products Regulatory Agency.
"Like other sectors in healthcare, the pharmaceutical industry is in the
midst of a highly transformative period," said Weiler. "Technological
shiftsand increased adoptions are impacting everything from drug
therapy development and discovery methods to innovative R&D partnerships
- and we remain committed to delivering the premier tools and services
our customers have come to expect. We applaud their continued dedication
to adopting the technologies, practices and standards that will help
ensure product efficacy and drug safety worldwide."
To view the full agenda and to register, please click here.
About Phase Forward
Phase Forward is a leading provider of integrated data management
solutions for clinical trials and drug safety. Phase Forward's products
and services have been utilized in over 10,000 clinical trials involving
more than 1,000,000 clinical trial study participants at over 300
organizations and regulatory agencies worldwide including: AstraZeneca,
Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S.
Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research
Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International,
Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare
Products Regulatory Agency. Additional information about Phase Forward
is available at www.phaseforward.com.
SOURCE: Phase Forward
Maria Sumner, +44 1628 640743
CHEN PR, Inc.
Juli Greenwood, 781-672-3137